Fosfonet

Fosfonet

SCHEMBL4607410

O=C(O)CP(=O)(O)O.[NaH].[NaH]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.93
LMNA P02545 1/20 0.93
HPGD P15428 1/20 0.93
TSHR P16473 1/20 0.93
BLM P54132 1/20 0.93
KMT2A Q03164 1/20 0.93
TDP1 Q9NUW8 1/20 0.93
ENO1 P06733 1/20 0.46
PGK1 P00558 1/20 0.45
PGK2 P07205 1/20 0.45
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
KDM4E B2RXH2 1/20 0.39
MMP2 P08253 1/20 0.39
THRB P10828 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
FOLH1 Q04609 4/20 0.39
USP2 O75604 1/20 0.39
GRIN2D O15399 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fosfonet SCHEMBL10490966 1.00 MEN1 (0.93) MEN1LMNAHPGDTSHRBLM
Fosfonet SCHEMBL15612 0.97
Fosfonet SCHEMBL26676053 0.93 MEN1 (0.93) MEN1LMNAHPGDTSHRBLM
Fosfonet SCHEMBL2801407 0.93
Fosfonet SCHEMBL28151124 0.93
Fosfonet SCHEMBL9162319 0.93
Fosfonet SCHEMBL11026013 0.93
Fosfonet SCHEMBL26676054 0.93
Fosfonet SCHEMBL15510455 0.93 MEN1 (0.93) MEN1LMNAHPGDTSHRBLM
Fosfonet SCHEMBL5521510 0.90 MEN1 (0.88) MEN1LMNAHPGDTSHRBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4806532-A ADMINISTERING PHOSPHONOFORMIC AND PHOSPHONOACETIC ACID AND SALTS; GLANDULAR DISORDERS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 1989-02-21 US claimed
EP-0652772-B2 HERPESVIRUS VACCINES HARVARD COLLEGE (US) 2008-07-23 EP disclosed
US-7223411-B1 Herpesvirus replication defective mutants DANA-FARBER CANCER INSTITUTE (US) 2007-05-29 US disclosed
EP-0739414-B1 HERPESVIRUS REPLICATION DEFECTIVE MUTANTS HARVARD COLLEGE (US) 2007-04-18 EP disclosed
EP-0652772-B1 HERPESVIRUS VACCINES HARVARD COLLEGE (US) 2002-11-20 EP disclosed
US-20020086035-A1 HERPEVIRUS REPLICATION DEFECTIVE MUTANTS DANA-FARBER CANCER INSTITUTE 2002-07-04 US disclosed
US-20020009462-A1 HERPESVIRUS REPLICATION DEFECTIVE MUTANTS DANA-FARBER CANCER INSTITUTE 2002-01-24 US disclosed
WO-1999006069-A1 HERPES VIRUS REPLICATION DEFECTIVE MUTANTS DANA FARBER CANCER INSTITUTE (US) 1999-02-11 WO disclosed
EP-0739414-A1 HERPESVIRUS REPLICATION DEFECTIVE MUTANTS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1996-10-30 EP disclosed
EP-0652772-A4 HERPESVIRUS VACCINES. HARVARD COLLEGE (US) 1996-05-29 EP disclosed
WO-1995018852-A1 HERPESVIRUS REPLICATION DEFECTIVE MUTANTS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1995-07-13 WO disclosed
EP-0652772-A1 HERPESVIRUS VACCINES THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1995-05-17 EP disclosed
WO-1994003207-A1 HERPESVIRUS VACCINES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1994-02-17 WO disclosed
EP-0043141-B1 PHARMACEUTICAL COMPOSITIONS HAVING ANTIVIRAL ACTIVITY FOR TOPICAL ADMINISTRATION AND THE USE OF 1-(SUBSTITUTED PHENYL)-5-(4-MORPHOLINYL)-1-PENTEN-3-ONE COMPOUNDS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING AN ANTIVIRAL EFFECT MERRELL DOW PHARMACEUTICALS INC. (US) 1984-09-12 EP disclosed
US-4400380-A HERBES VIRUS; TOPICAL MERRELL DOW PHARMACEUTICALS INC. (US) 1983-08-23 US disclosed
EP-0043141-A1 Pharmaceutical compositions having antiviral activity for topical administration and the use of 1-(substituted phenyl)-5-(4-morpholinyl)-1-penten-3-one compounds for the preparation of pharmaceutical compositions having an antiviral effect MERRELL DOW PHARMACEUTICALS INC. (US) 1982-01-06 EP disclosed